Search the Newsreel

Walleye Capital LLC Sells 677,212 Shares of Harmonic Inc. $HLIT

Walleye Capital LLC significantly reduced its stake in Harmonic Inc. by selling 677,212 shares, representing a 93.2% decrease. Despite this sell-off, institutional ownership in Harmonic remains high at 99.38%, with other firms like Jane Street and Norges Bank increasing or initiating positions. Analyst sentiment …

Harmony Gold Mining Co. Ltd. Sponsored ADR Revenue Breakdown – HAM:HAM

Harmony Gold Mining Co. Ltd. Sponsored ADR (HAM) generated 3.55 billion EUR in revenue last year. The Mponeng segment was the top performer, contributing 751.59 million EUR, an increase from the previous year. The majority of the revenue, 2.94 billion EUR, originated from South …

China Harmony Auto Holding Limited Revenue Breakdown – HKEX:3836

HMY|Harmony Gold Mining Company Ltd|Price:15.870|Chg%:+0.380

Harmony Gold Mining Company Ltd (HMY) has strong fundamentals and significant growth potential, although its valuation is considered fairly valued within the Metals & Mining industry. The stock price is currently trading sideways, with analysts rating it as 'Hold' and a high institutional ownership. …

Harmonic Inc (HLIT) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Harmonic Inc (HLIT), noting its current valuation score is 6.99, ranking 44 out of 54 in the Communications & Networking industry. It highlights the company's P/E ratio of -30.62, which is significantly below its recent high and …

HRMY|Harmony Biosciences Holdings Inc|Price:35.780|Chg%:+0.920

Harmony Biosciences Holdings Inc. (HRMY) shows strong fundamentals with high revenue and profit growth, despite its stock trading sideways recently. The company, focused on rare neurological diseases, has a "Buy" rating from analysts with a target price of $44.91, and its valuation is considered …

Harmony Gold Mining (HMY) Rallies 2.45% as Gold Price Support Lifts Mining Stocks - Parabolic SAR

ETFs Investing in Harmony Biosciences Holdings, Inc. Stocks

This article lists various ETFs that currently hold Harmony Biosciences Holdings, Inc. (HRMY) stocks, providing detailed information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year total return. The ETFs mainly focus on small-cap …

Harmony Biosciences (HRMY) Says Goodbye To Its CFO And Names An Interim Finance Chief

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Harmony Biosciences Holdings (NasdaqGM:HRMY) announced that Chief Financial Officer Glenn Reicin has resigned. The company named Stephen Mollichella as interim Principal Financial Officer, effective …

High court interdicts man over defamatory Whatsapp messages against Harmony Gold

The High Court in Johannesburg has issued an interdict against Frederik Johannes van As, preventing him from publishing false and defamatory statements against Harmony Gold. The ruling found that Van As's claims about Harmony Gold being responsible for Eskom disconnecting electricity to Deelkraal Village …

Harmonic Inc (HLIT) Shares Fall 3.7% -- GF Value Says Still Overvalued

Harmonic Inc (HLIT) shares dropped 3.7% on July 22, 2026, closing at $11.99, and are considered "Modestly Overvalued" according to GuruFocus' GF Value of $10.39. While the company has a strong GF Score of 78/100, indicating good overall quality with high growth and momentum, …

Harmony Biosciences (HRMY) officer details stock and option holdings

Stephen M. Mollichella, "INT PRINCIAL FINANCIAL OFFICER" at Harmony Biosciences (HRMY), has reported his initial beneficial ownership on a Form 3 filing. The filing details his holdings in stock options, restricted stock units, and directly owned common stock. These holdings include various vesting schedules …

Harmony Biosciences interim principal financial officer Stephen Mollichella files initial beneficial ownership statement

Stephen Mollichella, interim principal financial officer of Harmony Biosciences, has filed his initial beneficial ownership statement (Form 3). The filing indicates he holds 2,506 common shares, stock options for 48,472 shares with exercise prices between $30.69 and $38.01, and 12,013 restricted stock units. This …

Barometer Capital Management Inc. Grows Position in Harmony Gold Mining Company Limited $HMY

Barometer Capital Management Inc. significantly increased its stake in Harmony Gold Mining Company Limited (NYSE:HMY) by 1,118.8% in the first quarter, bringing its total holdings to 117,000 shares valued at $1.76 million. Other institutional investors also adjusted their positions, with hedge funds and institutions …

Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?

Harmony Biosciences (HRMY) shares surged 10% after the company reported stronger-than-expected preliminary second-quarter 2026 results, with Wakix net product revenue reaching a record $261 million. The company reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion, driven by robust demand and …

Harmony Biosciences Holdings Jumps 9.6% Amid Sector-Wide Rally

Harmony Biosciences (HRMY) shares surged 9.6% following a broad rally across the biotechnology sector. The increase brought the company's shares to $36.73, with trading volume reaching 1.2M shares. This sector-wide momentum, rather than company-specific news, appears to be the primary driver for the gains, …

Harmony Biosciences to report Q2 2026 results on August 4

Harmony Biosciences Holdings, Inc. will announce its Q2 2026 financial results on Tuesday, August 4, 2026, before market open. A conference call and webcast will be held at 8:30 a.m. ET to discuss these results, with investors able to participate via specific dial-in numbers …

Harmony Biosciences will host a live Q2 results webcast on Aug. 4

Harmony Biosciences (Nasdaq: HRMY) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, before the U.S. market opens. The company will also host a conference call and live webcast for investors and analysts at 8:30 a.m. ET on …

Bluepeak Reuses Existing Building Coax for Multi-Gigabit Broadband

Bluepeak is partnering with Harmonic to accelerate its fiber network rollout and expand into Multi-Dwelling Units (MDUs) across six states. By using Harmonic's cOS virtualized broadband platform, Pearl remote OLTs, and SeaStar optical nodes, Bluepeak can reuse existing in-building coax infrastructure to deliver multi-gigabit …

Harmony Gold Mining Reports Fatal Incident at TauTona Shaft

Harmonic : Bluepeak Taps Harmonic to Speed Up Fiber Rollout and Expand into MDUs

Bluepeak is partnering with Harmonic to accelerate its fiber network expansion and bring high-speed broadband to more communities and multi-dwelling units (MDUs). Utilizing Harmonic's cOS virtualized core, Pearl R-OLTs, and the SeaStar optical node, Bluepeak can strategically introduce PON services while maximizing existing infrastructure …

H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)

H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Harmony Biosciences Holdings Inc. (HRMY). The analyst also maintained a price target of $55.00 for the company's stock. This article is behind a paywall and requires a premium subscription to read the full …

H.C. Wainwright reiterates Harmony Biosciences stock rating on demand beat

H.C. Wainwright reiterated a Buy rating and a $55 price target for Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) after the company announced stronger-than-expected second-quarter revenue. The beat was attributed to increased demand, leading H.C. Wainwright to modestly raise its full-year 2026 net product revenue estimate …

Harmonic (HLIT) Projected to Announce Quarterly Earnings on Monday

Harmony Bio drops after CFO exit

Harmony Bio's stock fell sharply following the unexpected departure of its Chief Financial Officer. The company has not yet named a successor, leading to investor uncertainty. This executive change raises questions about the company's financial stability and future strategic direction.

HARMONIC INC. (NASDAQ: HLIT) SVP exercises RSUs, 1,031 shares withheld

Ronald J. Glahn, SVP of Global Sales, Broadband at Harmonic Inc. (NASDAQ: HLIT), reported exercising 3,750 restricted stock units and having 1,031 shares withheld for tax obligations at $12.99 per share on July 15, 2026. Following these transactions, Glahn directly owns 41,536 common shares …

Form 4 Harmonic Inc For: 17 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Harmonic Inc. (HLIT) pertaining to July 17. The Form 4 is a U.S. Securities and Exchange Commission document that must be filed by company insiders when they trade shares of their own company's …

HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition

Harmony Biosciences (HRMY) announced strong preliminary Q2 2026 net product revenues of $261 million for its drug Wakix, a 30% year-over-year increase, and reiterated its full-year guidance of $1.0 billion to $1.04 billion. Concurrently, the company announced the departure of CFO Glenn Reicin, with …

Harmony Biosciences reaffirms 2026 net revenue outlook of $1 billion-$1.04 billion

Harmony Biosciences has reaffirmed its net revenue guidance for WAKIX in 2026, projecting between $1 billion and $1.04 billion. This outlook is supported by strong preliminary second-quarter WAKIX net revenue of approximately $261 million, marking a 30% year-over-year increase and a 21% rise from …

Harmony Gold Mining Co. Ltd (HMY) Q4 2025 Earnings Report - Results, Call & Slides

Harmony Gold Mining (HMY) reported its Q4 2025 earnings, meeting EPS expectations at $0.57 while beating revenue forecasts with $2.17 billion, a 31.74% year-over-year increase. The company's actual revenue surpassed the expected $2.03 billion by $138.43 million. The earnings call took place on Thursday, …

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Harmony Biosciences announced record preliminary, unaudited net product revenue of approximately $261 million for WAKIX® in Q2 2026, a 30% year-over-year increase, and reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion. The company also announced the departure of …

Harmony Biosciences reports record Q2 WAKIX sales of $261M

Harmony Biosciences Holdings, Inc. announced record preliminary, unaudited second-quarter 2026 net product revenue of $261 million for WAKIX, representing a 30% year-over-year increase. The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, driven by strong demand and …

Harmony Biosciences Announces CFO Transition as Glenn Reicin Steps Down

Harmony Biosciences announced that CFO Glenn Reicin has stepped down, effective July 16, 2026, to pursue other opportunities. Stephen Mollichella, SVP and controller, has been appointed interim principal financial officer. The company also reported record preliminary second-quarter revenue of approximately $261 million for WAKIX® …

GUIDANCE: (HRMY) Harmony Biosciences Expects Q2 Wakix Net Product Revenue About $261M

Harmony Biosciences (HRMY) announced it expects its second-quarter Wakix net product revenue to be approximately $261 million. This projection indicates continued strong performance for their primary product. The financial guidance provides a positive outlook for the company's Q2 results.

Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement

Harmony Biosciences reported preliminary second-quarter net product revenue for WAKIX of approximately $261 million, a new record, and reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion. Concurrently, the company announced that CFO Glenn Reicin stepped down, with Stephen Mollichella appointed …

Harmony Bio stock drops after CFO exit (HRMY:NASDAQ)

Harmony Biosciences (HRMY) stock declined following the resignation of its Chief Financial Officer, Glenn Reicin, who left to pursue other career opportunities. Stephen Mollichella, the SVP and Controller, has been appointed as the Interim Principal Financial Officer to oversee financial operations for the rare …